A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 21
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PCLI
Long Form : plasma cell labeling index
No. Year Title Co-occurring Abbreviation
2016 Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. hs-CRP, IMM, MM, MR, OS, PFS, PR, SMM
2011 Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma. MM, RB1
2011 Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. ---
2005 [Effect of 2-methoxyestradiol on proliferation and apoptosis of myeloma cell lines]. TUNEL
2004 Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments. BrdU, MM, PBLI
2003 Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. EFS, LDH, MM, OS
2002 Bone marrow angiogenesis in multiple myeloma: effect of therapy. MVD
2001 A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. MM
2001 Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. CG, MM, Thal
10  2001 GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trial. GM-CSF
11  2001 Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. CR
12  2001 Thalidomide in the management of multiple myeloma. beta2m, CR, EFS, OS
13  2000 Effect of complete response on outcome following autologous stem cell transplantation for myeloma. CR, OS, PFS, SCT
14  1999 Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. ---
15  1999 Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. 7-AAD, MGUS, MM, PCAI, PCGI
16  1999 Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486. cIg
17  1998 Anti-myeloma activity of pamidronate in vivo. Ig
18  1998 S-phase induction by interleukin-6 followed by chemotherapy in patients with refractory multiple myeloma. AE, IL-6, LI, MM
19  1996 Multiple Myeloma: An Overview in 1996. MM, SMM
20  1995 Prognostic factors in multiple myeloma. beta 2m, IL-6, sIL-6R
21  1993 Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. beta 2m, CRP, MM, TK